Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Sell
38
PBH Quote, Financials, Valuation and Earnings
Last price:
$76.97
Seasonality move
:
2.59%
Day range:
$76.19 - $78.27
52-week range:
$57.95 - $86.36
Dividend yield:
0%
P/E ratio:
18.71x
P/S ratio:
3.47x
P/B ratio:
2.19x
Volume:
169.1K
Avg. volume:
254.1K
1-year change:
27.2%
Market cap:
$3.8B
Revenue:
$1.1B
EPS (TTM):
$4.11
Analysts' Opinion
-
Consensus RatingPrestige Consumer Healthcare has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Prestige Consumer Healthcare has an estimated upside of 9.82% from its current price of $76.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $76.88.
Fair Value
-
According to the consensus of 7 analysts, Prestige Consumer Healthcare has 9.82% upside to fair value with a price target of -- per share.
PBH vs. S&P 500
-
Over the past 5 trading days, Prestige Consumer Healthcare has underperformed the S&P 500 by -2.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Prestige Consumer Healthcare does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Prestige Consumer Healthcare revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Prestige Consumer Healthcare reported revenues of $283.8M.
Earnings Growth
-
Prestige Consumer Healthcare has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Prestige Consumer Healthcare reported earnings per share of $1.09.
Enterprise value:
4.8B
EV / Invested capital:
--
Price / LTM sales:
3.47x
EV / EBIT:
14.80x
EV / Revenue:
4.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
18.84x
Price / Operating cash flow:
15.15x
Enterprise value / EBITDA:
13.49x
Gross Profit (TTM):
$613.2M
Return On Assets:
6.2%
Net Income Margin (TTM):
18.54%
Return On Equity:
12.55%
Return On Invested Capital:
7.39%
Operating Margin:
29.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.1B | $1.1B | $286.3M | $283.8M | |
| Gross Profit | $625.1M | $618.9M | $613.2M | $160M | $157.4M | |
| Operating Income | $332.5M | $349.8M | $325.4M | $88.3M | $84.3M | |
| EBITDA | $362.3M | $11.1M | $355.8M | $95.7M | $91.9M | |
| Diluted EPS | $4.12 | -$1.66 | $4.11 | $1.07 | $1.09 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $269.9M | $304.8M | $336.7M | $388.2M | $380.7M | |
| Total Assets | $3.4B | $3.7B | $3.7B | $3.3B | $3.3B | |
| Current Liabilities | $136.1M | $148.9M | $152.3M | $129.7M | $106.9M | |
| Total Liabilities | $2.2B | $2.2B | $2.1B | $1.8B | $1.6B | |
| Total Equity | $1.3B | $1.5B | $1.6B | $1.5B | $1.7B | |
| Total Debt | $1.5B | $1.6B | $1.4B | $1.3B | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $245.2M | $224.5M | $263M | $62.5M | $69.8M | |
| Cash From Investing | -$26.9M | -$8.8M | -$23.7M | -$2.9M | -$2M | |
| Cash From Financing | -$217.1M | -$198.2M | -$250M | -$53.5M | -$51.2M | |
| Free Cash Flow | $236.4M | $215.7M | $254.6M | $59.5M | $67.8M | |
PBH
Sector
Market Cap
$3.8B
$49.2M
Price % of 52-Week High
89.02%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
27.2%
-30.94%
Beta (5-Year)
0.507
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$78.13
200-day SMA
Buy
Level
$72.17
Bollinger Bands (100)
Buy
Level
70.17 - 81.15
Chaikin Money Flow
Buy
Level
12.9M
20-day SMA
Sell
Level
$80.53
Relative Strength Index (RSI14)
Sell
Level
33.16
ADX Line
Sell
Level
23.82
Williams %R
Buy
Level
-90.9992
50-day SMA
Sell
Level
$80.05
MACD (12, 26)
Sell
Level
-1.05
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
877.6K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.6435)
Buy
CA Score
(Annual)
Level (-0.0304)
Buy
Beneish M-Score
(Annual)
Level (-2.4718)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.1102)
Buy
Piotroski F Score
(Annual)
Level (9)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Stock Forecast FAQ
In the current month, PBH has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The PBH average analyst price target in the past 3 months is --.
-
Where Will Prestige Consumer Healthcare Stock Be In 1 Year?
According to analysts, the consensus estimate is that Prestige Consumer Healthcare share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Prestige Consumer Healthcare?
Analysts are divided on their view about Prestige Consumer Healthcare share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Prestige Consumer Healthcare is a Sell and believe this share price will drop from its current level to --.
-
What Is Prestige Consumer Healthcare's Price Target?
The price target for Prestige Consumer Healthcare over the next 1-year time period is forecast to be -- according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is PBH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Prestige Consumer Healthcare is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PBH?
You can purchase shares of Prestige Consumer Healthcare via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Prestige Consumer Healthcare shares.
-
What Is The Prestige Consumer Healthcare Share Price Today?
Prestige Consumer Healthcare was last trading at $76.97 per share. This represents the most recent stock quote for Prestige Consumer Healthcare. Yesterday, Prestige Consumer Healthcare closed at $76.88 per share.
-
How To Buy Prestige Consumer Healthcare Stock Online?
In order to purchase Prestige Consumer Healthcare stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
